Sector: Biotech / Immunotherapy
Platform: StartEngine
Stage: Early Clinical
Valuation: $30M
Minimum Investment: $525
What They Do
CancerVax is developing an innovative cancer immunotherapy designed to empower the immune system to target and eliminate cancer cells—all while preserving healthy tissue.
Why It Might Be the Next Big Thing
Cancer treatments have advanced, but side effects and targeted effectiveness remain big challenges. CancerVax’s approach focuses on enhancing the immune response with minimal collateral damage, showing encouraging preclinical results.
Snapshot
Preclinical trials demonstrate strong tumor regression
Collaboration with UCLA researchers
Preparing for Phase 1 clinical trials
My Take
Biotech is always a challenging field, but CancerVax’s scientific foundation and strong academic collaborations make it a company to watch closely.
⬆️ Startup discoveries, delivered weekly.
Disclaimer: This blog post is for informational purposes only and does not constitute financial advice or investment solicitation.